公开(公告)号：EP3389645A1

公开(公告)日：2018-10-24

申请号：EP16876677.2

申请日：2016-12-15

申请人： Ignyta, Inc.

发明人： LI, Gang ,  WEI, Ge ,  HORNBY, Zachary D. ,  LIM, Jonathan Ee-Ren

IPC分类号： A61K31/00 ,  A61K31/416 ,  A61P35/00 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  A61K31/166 ,  A61K31/18 ,  A61K31/365 ,  A61K31/416 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/519 ,  A61K45/06 ,  C12Q1/68 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K2300/00

摘要： Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROSl, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.

公开(公告)号：EP3303382A1

公开(公告)日：2018-04-11

申请号：EP16804039.2

申请日：2016-05-25

申请人： Ignyta, Inc.

发明人： WEI, Ge

IPC分类号： C07K14/705 ,  C07K14/71 ,  C12N9/12 ,  A61K31/496 ,  A61P35/00 ,  A61P35/04

CPC分类号： A61K31/553 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C07K14/71 ,  C12N9/12 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

摘要： Disclosed herein are compositions and methods for treating cancer patients who have been previously treated with one or more chemotherapeutic agents and have developed at least partial resistance to such chemotherapeutic agents. Also disclosed are methods for selecting compounds suitable for treatment of cancer in a patient who has become resistant to an inhibitor of a receptor tyrosine kinase (RTK).